Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs CEP 11981 (Primary) ; Nivolumab (Primary)
  • Indications Carcinoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ERICA
  • Most Recent Events

    • 24 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2019.
    • 31 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.
    • 08 Oct 2018 Planned End Date changed from 1 Aug 2023 to 1 Oct 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top